The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...
Vessel density in the deep capillary plexus reflects disease activity and structural involvement in thyroid eye disease.
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...
PHOENIX — Historically, optic nerve involvement has been excluded from multiple sclerosis (MS) diagnostic criteria, but its inclusion in the upcoming 2024 McDonald Diagnostic Criteria is expected to ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback